SEC Filing Analysis: SPRUCE BIOSCIENCES, INC. (SPRB)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: The President and CFO, Samir M. Gharib, was awarded a substantial grant of 7,600 Restricted Stock Units (RSUs) with a notional value of over $670,000, representing a significant long-term incentive.
• Market Impact: Neutral. This is a standard, albeit large, executive compensation event, not an open-market transaction indicating a shift in insider sentiment.

Company Information

Field	Value
Company	SPRUCE BIOSCIENCES, INC.
Ticker Symbol	SPRB
CIK	0001683553
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Gharib Samir M.
CIK	0001533302
Title/Position	PRESIDENT AND CFO
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-11
Transaction Code	A (Grant)
Security Type	Restricted Stock Units
Shares Involved	7,600
Price Per Share	$0.00
Total Value	$0 (Notional Value ~$671,916)
Shares Owned After	7,616 (Common Stock) & 7,600 (RSUs)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Notional Value	~$671,916
% of Market Cap	~0.61%
Shares Transacted	7,600 RSUs
% of Shares Outstanding	Not Available
Post-Transaction Ownership	7,616 shares of Common Stock
Materiality Assessment	Significant (based on % of market cap)

Impact Evaluation

• Market Cap Context: For a small-cap company with a market capitalization of $110 million, an equity grant with a notional value of $671,916 is a material event. It represents a significant portion (0.61%) of the company's total value being allocated as executive compensation.
• Ownership Concentration: While the insider's direct holdings of 7,616 shares are modest, the new grant of 7,600 RSUs nearly doubles their potential equity stake, reinforcing their alignment with shareholder interests.
• Dilution Impact: The grant will lead to future dilution upon vesting. As shares outstanding data is not available, the exact percentage of dilution cannot be calculated, but it is a key factor for investors to monitor in small-cap biotech firms.
• Transaction Significance: The grant is rated as 'Significant' due to its value relative to the company's market cap. It underscores the board's confidence in the executive and provides a strong retention and performance incentive.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This filing reports an equity grant as part of an executive compensation package. It is not an open-market purchase or sale and therefore does not serve as a direct sentiment signal from the insider regarding the company's near-term stock performance.

Volume & Sentiment

• Expected Volume Impact: Low. The filing also disclosed minor, automatic 'sell-to-cover' transactions to satisfy tax obligations from vested RSUs. These are not discretionary trades and are too small to impact trading volume meaningfully.
• Sentiment Indicator: Neutral. The grant is a positive sign of long-term incentive alignment but is a standard corporate action.

Additional Context

Transaction Notes

• Vesting Schedule: The new grant of 7,600 RSUs has a vesting schedule where 25% vested immediately, with the remainder vesting annually over the next three years, contingent on continued service.
• Tax Withholding: The filing includes 'F' code transactions, which represent the automatic disposition of shares to the company to cover tax liabilities upon the vesting of RSUs. These are not discretionary sales by the insider. For example, on Dec 11, 680 shares were sold at $88.41 for this purpose.